Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688315.SS

HOLDREMOVE

Novogene Co., Ltd. · Healthcare · China · $870M · Avg Vol: $8M/d

60
StockRank
Q
64
V
34
M
52
P/E (TTM)
30.6x
ROE
6.4%
D/E
0.0x
Dividend %
0.4%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Novogene provides genomic sequencing services and solutions. Although it has a decent quality score (64), the gene sequencing service market is highly competitive, capital-intensive, and lacks the pricing power or proprietary platform characteristics of high-conviction CDMOs.

COMPANY DESCRIPTION

Novogene is a leading provider of genomic sequencing services and bioinformatics solutions, utilizing high-throughput next-generation sequencing (NGS) technologies. The company's competitive moat lies in its massive sequencing capacity, advanced automated laboratory workflows, and proprietary bioinformatics analysis pipelines. It operates as a dominant global service provider for academic, clinical, and pharmaceutical research institutions.

FINANCIAL SUMMARY

Year2022202320242025CAGR
Revenue285M296M312M327M4.7%
EPS0.070.070.070.06-2.3%
Shares400M416M416M416M+4.0%
Debt7M6M6M11M13.2%
Equity290M363M368M392M10.5%
Op CF45M49M57M32M-10.6%
Inv CF-52M-116M-76M-16M—
Fin CF-7M43M-27M-6M—
Loading...
PRICE (1M)-13.5%
1.811.952.092.232.36Apr 30May 26Jun 15
SMA 50SMA 200
Close
$1.82
RSI (14)
14.5
52W High
$2.69
From 52W High
0.7%

SCORE BREAKDOWN

Quality
64
ROIC
7.1%63.7
ROE
6.4%60.4
GP/Assets
24.8%56.0
Op. Margin
6.7%59.1
FCF/Assets
1.8%56.9
Piotroski
—83.5
Int. Cover
50.0x91.4
D/E Ratio
0.03x80.7
Current Ratio
2.62x47.5
Value
34
P/E (TTM)
30.6x36.3
EV/EBITDA
12.7x33.8
P/FCF
571.2x14.9
P/B
1.9x58.5
P/S
2.3x64.6
Div Yield
0.4%10.0
Momentum
52
52W High %
68%52.9
RS 6M
-17%59.9
SMA 50/200
0.98x55.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—53.7
Q Growth
-13%29.6

FUNDAMENTALS

Market Cap
$870M
P/E (Forward)
20.4x
Gross Margin
43.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688315.SS are excluded.

TickerCompanyMkt CapStockRankSignal
688315.SSNovogene Co., Ltd.(you)$870M60HOLD
688253.SSInnovita Biological Technology Co., Ltd.$1.1B58HOLD
300841.SZChengdu Kanghua Biological Products Co., Ltd.$917M67BUY
688105.SSNanjing Vazyme Biotech Co., Ltd$1.1B63HOLD
605116.SSAurisco Pharmaceutical Co.,Ltd.$1.2B56HOLD
002880.SZShenzhen Weiguang Biological Products Co., Ltd.$845M48HOLD
688202.SSShanghai Medicilon Inc.$1.2B53HOLD
002030.SZDaan Gene Co., Ltd.$1.5B57HOLD
002287.SZTibet Cheezheng Tibetan Medicine Co., Ltd.$1.8B60HOLD
688513.SSChengdu Easton Biopharmaceuticals Co., Ltd.$1.4B55HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.1%

Novogene Co., Ltd. (688315.SS) — Stock Score Summary

Novogene Co., Ltd. (688315.SS) has a MoatMap StockRank of 60/100 based on Quality (64/100), Value (34/100), and Momentum (52/100) factor scores. The current signal is HOLD. Novogene provides genomic sequencing services and solutions. Although it has a decent quality score (64), the gene sequencing service market is highly competitive, capital-intensive, and lacks the pricing power or proprietary platform characteristics of high-conviction CDMOs.

Novogene is a leading provider of genomic sequencing services and bioinformatics solutions, utilizing high-throughput next-generation sequencing (NGS) technologies. The company's competitive moat lies in its massive sequencing capacity, advanced automated laboratory workflows, and proprietary bioinformatics analysis pipelines. It operates as a dominant global service provider for academic, clinical, and pharmaceutical research institutions.

Key Financial Metrics

Price$1.82
Market Cap$870M
P/E (TTM)30.65
P/E (Forward)20.43
Price/Book1.86
Return on Equity6.4%
Return on Invested Capital7.1%
Debt/Equity2.54
Gross Margin43.0%
Operating Margin6.7%
Revenue Growth10.8%
Dividend Yield0.4%
Free Cash Flow$2M

Novogene Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Novogene Co., Ltd.’s (688315.SS) StockRank?
MoatMap’s StockRank for Novogene Co., Ltd. (688315.SS) is 60/100, with a Hold signal. It is a composite of Quality (64), Value (34), and Momentum (52) factor ranks across MoatMap’s 19,000+ stock universe.
Does Novogene Co., Ltd. have an economic moat?
Novogene Co., Ltd. (688315.SS) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Novogene Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Novogene Co., Ltd. (688315.SS) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Novogene Co., Ltd. in?
Novogene Co., Ltd. (688315.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688315.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock